Berlin – The pioneering scientists behind the first widely available mRNA COVID-19 vaccine are now turning their attention to a far more insidious foe: triple-negative breast cancer (TNBC). Uğur Şahin, CEO of BioNTech, and Özlem Türeci, the company’s Chief Medical Officer, are leading research that has yielded promising early results with a personalized mRNA vaccine designed to prevent recurrence of this aggressive form of the disease. This work builds upon decades of research into harnessing the power of the immune system to fight cancer, a journey that accelerated dramatically with the urgent need for a COVID-19 vaccine.
Triple-negative breast cancer, representing approximately 15-20% of all breast cancer diagnoses, is particularly challenging to treat. Unlike other breast cancers, it lacks the presence of estrogen receptors, progesterone receptors, and high levels of HER2 protein, meaning standard hormone therapies and HER2-targeted drugs are ineffective. This often leaves chemotherapy as the primary treatment option, and the cancer has a higher propensity for early metastasis, making recurrence a significant concern for patients. The development of effective immunotherapies for TNBC has long been a critical unmet medical need, and the work by Şahin and Türeci represents a significant step forward.
The research, recently published in the journal Nature, details a Phase 1 clinical trial evaluating an individualized mRNA vaccine targeting neoantigens – unique mutations found within each patient’s tumor. These neoantigens act as flags, signaling to the immune system that the cells are foreign and should be destroyed. By creating a vaccine tailored to each patient’s specific tumor profile, the researchers aimed to stimulate a robust and targeted immune response. The trial involved 14 patients who had undergone surgery and received either neoadjuvant (before surgery) or adjuvant (after surgery) chemotherapy.
Harnessing the Power of mRNA for Personalized Cancer Treatment
The core principle behind this approach is the ability of mRNA technology to rapidly design and manufacture vaccines specific to an individual’s cancer. As Özlem Türeci explained in a 2021 TED Talk with Uğur Şahin, the speed and flexibility of the mRNA platform were crucial in the rapid development of the COVID-19 vaccine. This same agility is now being applied to cancer treatment, allowing for the creation of highly personalized therapies. BioNTech’s success with the COVID-19 vaccine, developed in partnership with Pfizer, demonstrated the potential of mRNA technology to revolutionize medicine.
The study revealed that the vaccine successfully triggered a strong immune response in nearly all patients. Specifically, the vaccine prompted the generation of a high number of T cells – immune cells critical for recognizing and destroying cancer cells – that were directed against multiple proteins within the tumor. Importantly, these T cells remained functional for several years following vaccination. Remarkably, 11 of the 14 patients have remained free from cancer recurrence in the years since receiving the vaccine. Researchers identified two distinct types of T cell responses: those “ready to act” immediately and others exhibiting characteristics similar to stem cells, suggesting a potential for long-lasting immunity.
The vaccine regimen consisted of eight doses administered over a period of approximately two months: six weekly doses, two doses administered two weeks apart, and a final dose on day 64 of the treatment. The results showed a universal response, with all participants demonstrating an immune response against at least one of their tumor’s targets. In 86% of patients, these anti-tumor defenses remained detectable for periods ranging from one to six years without the need for booster doses. While the treatment wasn’t effective in three patients – whereas one of those patients eventually recovered – the researchers emphasize that the vaccine is “safe, well-tolerated, and highly immunogenic in TNBC,” a cancer characterized by a low to moderate mutational burden.
The Role of Neoantigens and Individualized Approaches
The concept of neoantigens is central to this innovative approach. Cancer cells accumulate genetic mutations over time, leading to the production of altered proteins – these are the neoantigens. Because these proteins are not found in healthy cells, they can be recognized by the immune system as foreign. However, the immune system often fails to mount a sufficient response against these neoantigens. The mRNA vaccine aims to overcome this limitation by presenting these neoantigens to the immune system in a way that triggers a strong and sustained anti-tumor response. Özlem Türeci’s background as a physician and scientist has been instrumental in translating this complex scientific concept into a viable therapeutic strategy.
The induction of these cells with regenerative potential is considered a key finding for long-term immunity. This suggests that the vaccine not only stimulates an immediate immune response but also establishes a memory within the immune system, allowing it to quickly recognize and eliminate any recurring cancer cells. This represents a crucial distinction from traditional cancer treatments, which often focus on killing existing cancer cells but do not provide lasting protection against recurrence.
BioNTech’s Continued Innovation in Immunotherapy
BioNTech’s journey from a relatively unknown biotechnology company to a global leader in mRNA technology is a testament to the power of scientific innovation, and perseverance. Founded in 2008 by Uğur Şahin and Özlem Türeci, the company initially focused on developing individualized cancer immunotherapies. Prior to BioNTech’s success with the COVID-19 vaccine, Türeci served as CEO and Chief Medical Officer of Ganymed Pharmaceuticals AG, further demonstrating her leadership in the biotechnology sector. The rapid development and deployment of the COVID-19 vaccine provided BioNTech with invaluable experience and resources, which are now being channeled into advancing its cancer immunotherapy programs.
The company is currently conducting clinical trials evaluating mRNA vaccines for a variety of other cancers, including melanoma, lung cancer, and pancreatic cancer. The goal is to develop a platform technology that can be adapted to target a wide range of cancers, offering hope to patients who have limited treatment options. BioNTech’s research and development efforts are focused on both neoantigen-specific and non-neoantigen-specific mRNA cancer vaccines, which can be individually tailored and produced on demand based on the genetic profile of a patient’s tumor.
While the results of the TNBC vaccine trial are highly encouraging, it’s critical to note that this is still early-stage research. Larger, randomized clinical trials will be needed to confirm these findings and determine the long-term efficacy and safety of the vaccine. However, the initial data suggest that personalized mRNA vaccines have the potential to transform cancer treatment, offering a new and effective way to fight this devastating disease. The next steps involve expanding the clinical trials to include a larger and more diverse patient population, as well as exploring combinations with other cancer therapies.
The work of Şahin and Türeci represents a paradigm shift in cancer treatment, moving away from a one-size-fits-all approach towards personalized therapies tailored to the unique characteristics of each patient’s tumor. This innovative approach holds immense promise for improving outcomes for patients with TNBC and other aggressive cancers, offering a beacon of hope in the ongoing fight against this global health challenge.
Researchers will continue to monitor the patients enrolled in the initial trial and are actively recruiting participants for larger studies. Updates on the progress of these trials will be available through BioNTech’s website and scientific publications. The future of cancer treatment may well lie in harnessing the power of the immune system, and the pioneering work of Uğur Şahin and Özlem Türeci is leading the way.
Do you have questions about personalized cancer vaccines or the latest advancements in immunotherapy? Share your thoughts and comments below.